NXL (Nexalin Technology) Valuation Rank

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Nexalin Technology Valuation Rank Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Executives

David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133